Niagen Bioscience, Inc.
NAGE
$10.10
$0.373.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.47% | 282.27% | 12,620.00% | 96.95% | -531.58% |
| Total Depreciation and Amortization | -45.53% | -2.19% | -1.08% | 71.30% | -42.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 98.62% | -643.45% | -38.59% | 0.33% | 13.04% |
| Change in Net Operating Assets | -47.54% | 916.10% | 127.38% | -185.69% | 29.50% |
| Cash from Operations | -8.16% | 145.58% | 1,423.86% | -189.49% | -54.55% |
| Capital Expenditure | 53.62% | -68.29% | -241.67% | 70.73% | -95.24% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 53.62% | -228.57% | -75.00% | 70.73% | -95.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -50.00% | 50.00% | -100.00% | 33.33% | -200.00% |
| Issuance of Common Stock | -17.86% | 263.47% | 74.41% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 85.37% | -- | -- | 100.00% | 85.33% |
| Cash from Financing | -17.16% | 260.73% | 74.33% | 4,357.14% | 81.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.65% | 171.70% | 1,310.31% | 33.33% | -56.52% |